[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100529603":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":10,"centralContacts":24,"locations":31,"responsibleParty":46,"collaborators":10,"id":48,"slug":49,"hasResults":50,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":50,"sex":56,"minAge":57,"maxAge":10,"enrollmentInfo":58,"targetDuration":10,"studyType":61,"phases":10,"briefSummary":62,"conditions":63,"keywords":66,"overallStatus":71,"whyStopped":10,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":81},{"fullName":5,"class":6},"Hospices Civils de Lyon","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"MDS patients",null,"Adult patients with myelodysplastic syndrome or suspected myelodysplastic syndrome according to the criteria defined by the World Health Organization:\n\n* one or more cytopenias,\n* and\u002For dysplasia of one or more lines,\n* and\u002For bone marrow blastosis\n* and\u002For sideroblasts in medullary crowns\n* and\u002For genetic\u002Fcytogenetic abnormalities characteristic of MDS.\n* Whatever the R-IPSS stage (Revised International Prognostic Scoring System)\n* No history of cytotoxic treatment (hydroxycarbamide, azacytidine)",[13],"Biological: Collection of EDTA (disodium salt of ethylenediaminetetraacetic acid) tubes of marrow during routine care",{"label":15,"type":10,"description":16,"interventionNames":17},"AML patients","Adult patients with suspected de novo acute myeloid leukemia at initial management",[13],[19],{"type":20,"name":21,"description":22,"armGroupLabels":23,"otherNames":10},"BIOLOGICAL","Collection of EDTA (disodium salt of ethylenediaminetetraacetic acid) tubes of marrow during routine care","When bone marrow is collected as part of a patient's care (diagnosis, follow-up, suspected AML\u002FMDS hemopathy), one or two additional EDTA tubes of marrow are collected. Certain hematological data (NFP, genetic and molecular characteristics) will be collected in anonymized form and correlated with the BMP pathway alterations measured.",[15,9],[25],{"name":26,"role":27,"phone":28,"phoneExt":29,"email":30},"Maël MD Heiblig","CONTACT","0478864340","+33","Mael.heiblig@chu-lyon.fr",[32],{"facility":5,"status":10,"city":33,"state":10,"zip":34,"country":35,"countryCode":36,"cosmosGeoPoint":37,"geoPoint":42,"contacts":43},"Lyon","69229","France","FR",{"type":38,"coordinates":39},"Point",[40,41],4.84789,45.74906,{"lat":41,"lon":40},[44],{"name":45,"role":27,"phone":10,"phoneExt":10,"email":10},"Maël MD HEIBLIG",{"type":47,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100529603","role-of-bmp-pathway-in-mds-progression-100529603",false,"NCT06175923","Role of BMP Pathway in MDS Progression","Role of the BMP Pathway in Myelodysplastic Syndromes Progression and in the Transition to Acute Myeloid Leukemia","BMP-MDS","Inclusion Criteria:\n\n* Adult patients with myelodysplastic syndrome or suspected myelodysplastic syndrome according to the criteria defined by the World Health Organization Or\n* Adult patient with suspicion of de novo acute myeloid leukemia at initial treatment\n\nExclusion Criteria:\n\n* Frontier MDS\u002Fmyeloproliferative syndromes including chronic myelomonocytic leukemia\n* MDS and AML having already benefited from cytotoxic treatment including hydroxycarbamide, azacytidine, intensive chemotherapy\n* Patients objecting to their inclusion in the study\n* Pregnant or breastfeeding women\n* Patients under legal protection measure","ALL","20 Years",{"count":59,"type":60},60,"ESTIMATED","OBSERVATIONAL","Myelodysplastic syndromes (MDS) are hematological cancers that can progress to acute myelogenous leukemia (AML). The involvement of the microenvironment in the maintenance, resistance and evolution of MDS is increasingly described.\n\nThe Bone Morphogenetic Protein (BMP) pathway is involved in numerous functions, including self-renewal of the hematopoietic stem cell compartment and the regulation of hematopoiesis, via interaction with bone marrow stromal cells. Investigators have demonstrated its involvement in chronic myeloid leukemia (CML) and AML, in particular via the activation of TWIST1, ΔNp73, NANOG; it is responsible for an increased state of quiescence of certain cancer stem cells and their resistance.\n\nPreliminary results based on the analysis of large databases suggest that the BMP pathway is also altered early in MDS. This study explores the alteration of this pathway in MDS and its involvement in the transformation into AML.\n\nIf appropriate, the BMP pathway could constitute a very promising therapeutic target to combat transformation into AML.",[64,65],"Myelodysplastic Syndromes","Acute Myelogenous Leukemia",[67,68,69,70],"BMP","MSC","MDS","microenvironment","NOT_YET_RECRUITING","2024-01-19",{"date":74,"type":75},"2024-01-23","ACTUAL",{"date":77,"type":60},"2024-01-27",{"date":79,"type":60},"2034-01-27",{"name":5,"class":6},1]